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BACKGROUND: Colorectal cancer (CRC) is the second cause of cancer-related death in the Western world. Much of the CRC genetic
risk remains unidentified and may be attributable to a large number of common, low-penetrance genetic variants. Genetic linkage
studies in CRC families have reported additional association with regions 9q22–31, 3q21–24, 7q31, 11q, 14q and 22q. There are
several plausible candidate genes for CRC susceptibility within the aforementioned linkage regions including PTCH1, XPA and TGFBR1
in 9q22–31, and EPHB1 and MRAS in 3q21–q24.
METHODS: CRC cases and matched controls were from EPICOLON, a prospective, multicentre, nationwide Spanish initiative,
composed of two independent phases. Phase 1 corresponded to 515 CRC cases and 515 controls, whereas phase 2 consisted of 901
CRC cases and 909 controls. Genotyping was performed for 172 single-nucleotide polymorphisms (SNPs) in 84 genes located within
regions 9q22–31 and 3q21–q24.
RESULTS: None of the 172 SNPs analysed in our study could be formally associated with CRC risk. However, rs1444601 (TOPBP1) and
rs13088006 (CDV3) in region 3q22 showed interesting results and may have an effect on CRC risk.
CONCLUSIONS: TOPBP1 and CDV3 genetic variants on region 3q22 may modulate CRC risk. Further validation and meta-analysis should
be undertaken in larger CRC cohorts.
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Colorectal cancer (CRC) continues to be a major public health
problem, although it is a preventable and potentially curable
neoplasm. Colorectal cancer is the second most common cancer in
Western countries and it also represents the second leading cause
of cancer-related death among men and women (Ferlay et al,
2010). Genetic and environmental factors are important in its
pathogenesis. Although the majority of CRC is sporadic, inherited
susceptibility is relevant in about 30–35% of cases. Germline
mutations in known genes such as APC and the DNA mismatch
repair family account for o6% of cases (Pin˜ol et al, 2005;
Jasperson et al, 2010). Much of the remaining genetic risk may be
attributable to a large number of common, low-penetrance genetic
variants each exerting a small influence on risk and following a
polygenic model of inheritance (Balmain et al, 2003).
Genetic association studies are among the possible approaches
to identify genes that underlie common diseases, either by
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candidate gene selection or GWAS. Recent GWASs have robustly
demonstrated that common genetic variation contributes to the
risk of developing CRC, and an increasing number of genomic
regions have been shown to be associated with CRC risk. So far, 14
common, low-penetrant genetic variants have been identified for
CRC susceptibility on 8q24.21, 18q21.1, 15q13.3, 8q23.3, 10p14,
11q23.1, 14q22.2, 16q22.1, 19q13, 20p12.3, 1q41, 3q26.2, 12q13.13
and 20q13.33 (Tenesa and Dunlop, 2009; Houlston et al, 2010).
Previously, genetic linkage studies in CRC families additionally
reported association with regions 9q22–31 (Wiesner et al, 2003;
Skoglund et al, 2006; Kemp et al, 2006a; Gray-McGuire et al, 2010),
3q21–24 (Kemp et al, 2006b; Papaemmanuil et al, 2008; Picelli
et al, 2008; Middeldorp et al, 2010), 7q31 (Neklason et al, 2008),
11q, 14q and 22q (Djureinovic et al, 2006). Wiesner et al (2003)
reported genetic linkage to chromosomal region 9q22.2–31.2 in a
set of 74 affected sibling pairs from 53 kindred with multiple CRC
and/or advanced colorectal adenoma cases. Subsequently,
Skoglund et al (2006) confirmed, in one extended family, a linkage
region on 9q22.32– 31.1 associated with adenoma and CRC
predisposition. In addition, Kemp et al (2006a) suggested further
evidence of a CRC susceptibility locus on 9q22.32 –q31.1 in 57 CRC
families from the United Kingdom. Recently, Gray-McGuire et al
(2010) refined CRC linkage on 9q22–31 and narrowed it down to a
151-kb region using an additional cohort of 69 independent CRC
kindred. On the other hand, Kemp et al (2006b) provided evidence
of the existence of a novel CRC predisposition region on
chromosome 3q21–q24 through a genome-wide linkage analysis
in 69 CRC families, which was subsequently extended by
Papaemmanuil et al (2008) in 34 additional CRC families. Two
other independent linkage studies have also pointed out a region
on chromosome 3q21–q24 to be linked to CRC susceptibility
(Picelli et al, 2008; Middeldorp et al, 2010).
There are several plausible candidate genes for CRC suscept-
ibility within the aforementioned linkage regions, including
PTCH1, XPA and TGFBR1 in 9q22–31, and EPHB1 and MRAS in
3q21–q24. However, variations within these genes or other
interesting candidate genes have been hardly evaluated in case–
control genetic association studies to assess them as CRC genetic
susceptibility components.
Hence, the aim of our study was to select candidate genes/
variants from 9q22 and 3q22 and to consider their potential
implications in CRC genetic susceptibility. Thus, we performed a
two-phase case– control association study in the EPICOLON
cohort (1416 CRC cases and 1424 controls) analysing 172 single-
nucleotide polymorphisms (SNPs) within 84 genes located within
these chromosomal regions.
PATIENTS AND METHODS
Study subjects
We included 1416 CRC patients and 1424 controls from the
Spanish population. Cases and healthy controls were recruited in
the EPICOLON project, a prospective, multicentre, population-
based cohort, in two independent phases (2000– 2001 and 2006–
2008). The EPICOLON cohort has been described in detail
elsewhere (Pin˜ol et al, 2005; Abulı´ et al, 2010). The mean age at
CRC diagnosis was 70 years, early-onset CRC (o50) was present at
a 4– 5% frequency and B15% of cases has a first-degree relative
with CRC. Subjects in the discovery phase (phase 1) included 515
CRC cases and 515 controls. Subjects in the replication phase
(phase 2) comprised 901 CRC cases and 909 controls. Exclusion
criteria for the case–control study were hereditary CRC forms
(familial adenomatous polyposis, MUTYH-associated polyposis
and Lynch’s syndrome) and personal history of inflammatory
bowel disease. Cases and controls were gender and age matched
(±5 years) and controls lacked personal and family cancer history.
DNA samples were extracted as described previously (Castellvı´-Bel
et al, 2007; Ferna´ndez-Rozadilla et al, 2010). This study was
approved by the institutional ethics committees of each participat-
ing hospital and written informed consent was obtained from all
individuals.
Candidate gene selection
Linkage region on chromosome 9 was delimited between
90 795 373 and 106 903 700 bp, spanning 16.1 Mb, whereas linkage
region on chromosome 3 was contained between 129 274 056 and
140 286 919 bp covering 11.01 Mb (according to NCBI genome
build 37.2, http://www.ncbi.nlm.nih.gov). Gene selection was
biased to include genes with previous evidence of being involved
in cancer (e.g., DNA repair genes), with a function compatible with
cancer involvement (e.g., cell cycle) or with a gene ontology term
suggestive of a role in cancer (e.g., DNA binding). Pseudogenes
were excluded from gene selection. In all, 41 out of 207 genes and
43 out of 123 genes were selected within the delimited regions on
chromosomes 9 and 3, respectively, adding up to a total of 84.
Description of all selected genes is summarised in Supplementary
Tables 1 and 2. It is worth mentioning that gene selection was
limited as it was based on current gene function annotations on
available databases. Nowadays, it is estimated that gene function is
known for 10 –30% of genes in the human genome.
SNP selection and genotyping
Overall, 94 SNPs from 41 genes and 78 SNPs from 43 genes were
selected in regions 9q22 and 3q22, respectively, adding up to 172
variants. Single-nucleotide polymorphisms were chosen using only
a direct strategy, selecting variants within each gene with a putative
functional effect by using PupaSuite, a web tool used for the
selection of genetic variants with potential phenotypic effect
(Conde et al, 2006; http://pupasuite.bioinfo.cipf.es). TagSNPs were
not selected in our study and segregation in the same haplotype
block was not considered for exclusion. Single-nucleotide poly-
morphisms were always prioritised if they were coding, evolu-
tionary conserved in mouse, with a putative regulatory effect in
promoter, intronic or 30-UTR regions, or involved in microRNAs
binding. Minor allele frequency (MAF) was always 45%. One or
two SNPs were usually selected from each gene, although more
SNPs per gene were included if gene functionality was considered
more important for CRC susceptibility. A description of all
selected SNPs from regions 9q22 and 3q22 is available in
Supplementary Tables 1 and 2, respectively.
High-throughput genotyping was performed according to the
manufacturer’s instructions using the SNPlex system (Applied
Biosystems, Foster City, CA, USA), or the single-base primer
extension chemistry matrix-assisted laser desorption/ionisation
time-of-flight mass spectrometry detection platform (Sequenom
Inc., San Diego, CA, USA). For rs11466445 (TGFBR1), a specific
PCR followed by single-strand conformation polymorphism
detection was performed to identify a 9-bp allele difference
(deletion of GGCGGCGGC). This SNP was not possible to genotype
with high-throughput technology and it was only genotyped in
EPICOLON 1 samples. Genotyping was performed at the Santiago
de Compostela and Barcelona nodes of the Spanish National
Genotyping Centre (www.cegen.org).
Statistical analysis
Genotyping quality control in both cohorts was performed using
PLINK v1.03 (Purcell et al, 2007; http://pngu.mgh.harvard.edu/
purcell/plink) excluding SNPs with genotype success rates below
90% and individuals with genotype success rates below 80%.
Departure from the Hardy –Weinberg equilibrium for all biallelic
SNP markers was tested in controls using a w2-test with a single
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degree of freedom to exclude genotyping artefacts. After quality
control, 991 samples (487 cases and 504 controls) and 170 SNPs
remained to be analysed on phase 1. On the other hand, 1685
samples (847 cases and 838 controls) and 20 SNPs remained to be
analysed on phase 2. There was no sign of underlying population
stratification in EPICOLON as tested by an independent study
(Ferna´ndez-Rozadilla et al, 2010). Genotypic/allelic association tests
and logistic regression analyses were performed using PLINK v1.03.
Genotype frequency differences were evaluated by regression
analysis for allelic, genotypic, dominant and recessive models of
inheritance. We estimated the crude odds ratio (OR) and 95%
confidence intervals. If one of the genotypes had a frequency o5,
then Fisher’s exact test was used. In EPICOLON phase 1, a liberal P-
value threshold (P-value o0.05) was used to avoid false-negative
results. We then validated statistically significant phase 1 results by
replicating them in another independent CRC cohort (EPICOLON
phase 2). Although they were not statistically significant in
EPICOLON phase 1, rs1800975 (XPA) and rs357564 (PTCH1) were
also moved forward to phase 2 because of their biological interest.
Finally, to address the issue of multiple testing, we used Bonferroni’s
correction (P¼ 0.0025 for 20 SNPs). Study power was estimated
using CATS software (Skol et al, 2006). Association results in
EPICOLON for some SNPs were also evaluated in two cohorts
described in a previous GWAS (Tomlinson et al, 2007), either by
checking the original variant or a proxy SNP highly correlated with
it (r240.7). These cohorts were CORGI (1432 CRC cases and 2697
controls) and VQ58 (928 CRC cases and 931 controls).
RESULTS
After genotyping quality control, data from 170 SNPs in 84 genes
were available in EPICOLON phase 1 and all SNPs analysed were in
the Hardy– Weinberg equilibrium in controls (P-value 40. 01).
After association analysis in EPICOLON phase 1, 21 SNPs were
statistically significant with an unadjusted P-valueo0.05 in any of
the tested inheritance models (Table 1). It is worth mentioning that
eight of the significant SNPs in phase 1 were located in region
9q22, three of them in the ABCA1 gene. On the other hand, the
remaining 13 significant SNPs were located in region 3q22, 2 SNPs
each in the A4GNT and ARMC8 genes.
In the EPICOLON phase 1 cohort, a liberal P-value threshold
(P-value o0.05) was used to avoid false-negative results. We then
validated statistically significant phase 1 results by replicating
them in another independent CRC cohort (EPICOLON phase 2).
Two SNPs with non-statistically significant results in phase 1 from
relevant genes in 9q22 (rs357564 in PTCH1 and rs1800975 in XPA)
were pushed forward to phase 2 to achieve results in both cohorts.
In addition, rs11466445 in TGFBR1, although being borderline
significant in EPICOLON phase 1, was not genotyped in phase 2
because of incompatibility with the used high-throughput
technology. Genotype frequencies of all variants in the EPICOLON
phase 2 control population fitted the Hardy –Weinberg equili-
brium (P40.01), except for rs12236219 and rs3738000 that were
excluded. Therefore, results were available in EPICOLON phases 1
and 2 for the remaining 20 SNPs. For them, we performed a joint
analysis of data combining both cohorts (1361 CRC cases and 1342
controls) to improve statistical power, as suggested previously
(Skol et al, 2006).
Taking into account both EPICOLON phases, six SNPs in region
3q22 (rs1444601, rs13088006, rs939453, rs1131597, rs10934954 and
rs2071387) maintained statistical significance with unadjusted
P-value in the overall analysis. Association analysis for these six
SNPs in the discovery, replication and overall cohorts is shown in
Table 2. Among them, the most interesting results were achieved
by rs1444601 in TOPBP1 and rs13088006 in CDV3, maintaining
statistical significance with an unadjusted P-value in all phases.
However, it is worth mentioning that these observed associations
would not be present if Bonferroni’s correction for multiple testing
was applied (P¼ 0.0025 for 20 SNPs) and, therefore, they should be
considered formally as not statistically significant.
In addition, association results for rs1444601, rs13088006,
rs939453, rs1131597, rs10934954 and rs2071387 were also
evaluated in two cohorts described in a previous GWAS
(Tomlinson et al, 2007), either by checking the original variant
or a proxy SNP highly correlated with it (r240.7) (Table 3). None
of these six variants were significantly associated with CRC risk in
this previous GWAS.
Table 1 SNPs with statistically significant results in EPICOLON stage 1 in the candidate-gene approach for regions 9q22 and 3q22
SNP_ID Gene Location/relevance Alleles
MAF
cases
MAF
controls Test
GT counts
cases
GT counts
controls OR (95% CI) P-value
rs4149338 ABCA1 9q22/intron, triplex, mcons C/T 0.241 0.285 Dom 201/280 248/252 0.73 (0.57–0.94) 0.0141
rs2515618 ABCA1 9q22/intron, triplex, mcons G/A 0.255 0.278 Dom 213/287 250/260 0.77 (0.60–0.99) 0.0406
rs4149339 ABCA1 9q22/miss, ESE, mcons C/T 0.217 0.278 Dom 183/300 247/257 0.63 (0.49–0.82) 0.00043
rs10991898 AUH 9q22/intron, triplex, mcons C/T 0.095 0.119 Dom 87/394 117/386 0.73 (0.53–0.99) 0.0493a
rs589362 C9ORF102 9q22/30UTR, ESE, mcons C/G 0.320 0.358 Dom 257/223 306/198 0.75 (0.58–0.96) 0.0230
rs10123342 NOL8 9q22/promoter, mcons T/G 0.343 0.394 Rec 52/433 86/407 0.57 (0.39–0.82) 0.0025
rs11466445 TGFBR1 9q22/3 AA deletion
(GGCGGCGGC), mcons
3AA/- 0.084 0.109 Dom 77/406 105/399 0.72 (0.52–0.99) 0.0491a
rs12236219 ZNF169 9q22/miss, ESE, mcons C/T 0.031 0.068 Allelic 30/940 69/939 0.43 (0.28–0.67) 0.00012a
rs2246945 A4GNT 3q22/miss, ESE, mcons A/C 0.289 0.325 Rec 37/430 59/431 0.63 (0.40–0.97) 0.0340
rs2346747 A4GNT 3q22/promoter, mcons G/A 0.317 0.352 Rec 46/434 69/417 0.64 (0.43–0.95) 0.0268
rs329387 ARMC8 3q22/intron, triplex, mcons G/A 0.450 0.502 Dom 317/151 377/124 0.69 (0.52–0.91) 0.0095
rs939453 ARMC8 3q22/triplex, mcons C/A 0.422 0.484 Allelic 404/554 484/516 0.78 (0.65–0.93) 0.0056
rs13088006 CDV3 3q22/intron, triplex, mcons T/C 0.232 0.256 Rec 22/458 40/448 0.54 (0.31–0.92) 0.0217
rs1673607 CEP70 3q22/miss, ESE, ESS, mcons A/G 0.472 0.501 Rec 108/388 140/367 0.73 (0.55–0.97) 0.0321
rs811322 FAIM 3q22/synon, ESE A/G 0.456 0.485 Rec 98/389 128/373 0.73 (0.54–0.99) 0.0423
rs108858 IL20RB 3q22/30UTR, ESE A/G 0.433 0.475 Dom 313/161 362/136 0.73 (0.56–0.96) 0.0243
rs3738000 NEK11 3q22/miss, mcons T/A 0.273 0.301 Dom 218/262 261/239 0.76 (0.59–0.98) 0.0337
rs10934954 PIK3R4 3q22/synon, ESS C/T 0.242 0.204 Rec 33/446 19/481 1.87 (1.05–3.34) 0.0311
rs2071387 RBP1 3q22/intron, mcons T/C 0.170 0.177 Rec 8/475 22/478 0.37 (0.16–0.83) 0.0124
rs1131597 SLCO2A1 3q22/30UTR, mcons G/A 0.303 0.379 Allelic 289/665 380/622 0.71 (0.59–0.86) 0.00038
rs1444601 TOPBP1 3q22/synon, mcons A/G 0.238 0.281 Allelic 231/739 282/720 0.80 (0.65–0.98) 0.0284
Abbreviations: AA¼ amino acid; CI¼ confidence interval; Dom¼ dominant; ESE¼ exonic splicing enhancer; ESS¼ exonic splicing silencer; GT¼ genotype; MAF¼minor allele
frequency; mcons¼ conserved in mouse; miss¼missense; Rec¼ recessive; SNP_ID¼ SNP identification; synon¼ synonymous; intron¼ intronic; UTR¼ untranslated region.
Results are shown according to the best fitting-model. aIf one of the genotypes had a frequency o5, then Fisher’s exact test was used.
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DISCUSSION
Several genetic linkage studies in CRC families have previously
reported disease association with chromosomal regions 9q22– 31
and 3q21–24. There are several plausible candidate genes for CRC
susceptibility within the aforementioned linkage regions including
PTCH1, XPA and TGFBR1 in 9q22–31, and EPHB1 and MRAS in
3q21–q24. Therefore, our study selected candidate genes/variants
from 9q22 and 3q22 and evaluated its potential implication in CRC
genetic susceptibility. For these means, we performed a two-phase
case–control association study in the EPICOLON cohort (1416
CRC cases and 1424 controls) analysing 172 SNPs within 84 genes
located within chromosomal regions 9q22–31 and 3q21– q24
potentially involved in cancer. For instance, among the selected
genes were phosphatidylinositol 3-kinases, a gene family involved
in multiple cellular functions related to cancer, or MRAS, part of
the Ras signalling extensively dysregulated in carcinogenesis
(Bunney and Katan, 2010).
The TGFBR1 gene located in chromosomal region 9q22 was
also incorporated in our study, and SNPs within this gene
included rs11466445, a polymorphic 9-bp deletion with contro-
versial results regarding its association with CRC risk (Kaklamani
et al, 2003; Skoglund et al, 2007). Our results in the first
phase showed a borderline significant association (unadjusted
P-value ¼ 0.0491, dominant inheritance) but did not reach
statistical significance after multiple-testing correction, suggesting
that rs11466445 does not increase CRC risk. We also screened
six other TGFBR1 variants with potential pathogenic effects and
found no evidence of CRC risk association, in agreement with
recent studies in Spanish and northern European populations
(Castillejo et al, 2009; Carvajal-Carmona et al, 2010). Besides,
the transforming growth factor-b (TGF-b) pathway has been
Table 2 Summary results for the six most significant SNPs in all EPICOLON phases
Discovery Replication Overall
SNP Gene Test OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
rs1444601 TOPBP1 Geno 0.77 (0.59–1.00) 0.93 (0.76–1.14) 0.88 (0.75–1.03)
0.69 (0.42–1.13) 0.087 0.64 (0.43–0.97) 0.097 0.65 (0.48–0.89) 0.015
Allelic 0.80 (0.65–0.98) 0.028 0.86 (0.74–1.01) 0.070 0.84(0.75–0.95) 0.0054
Dom 0.76 (0.59–0.97) 0.030 0.88 (0.73–1.07) 40.1 0.84 (0.72–0.98) 0.023
Rec 0.77 (0.47–1.24) 0.279 0.66 (0.45–0.99) 0.041 0.69 (0.51–0.94) 0.016
rs13088006 CDV3 Geno 1.05 (0.80–0.37) 0.83 (0.68–1.03) 0.92 (0.78–1.08)
0.55 (0.32–0.95) 0.067 0.73 (0.46–1.16) 40.1 0.66 (0.47–0.92) 0.043
Allelic 0.88 (0.71–1.08) 0.222 0.84 (0.71–0.99) 0.042 0.87 (0.76–0.98) 0.025
Dom 0.96 (0.74–1.24) 0.715 0.82 (0.67–0.99) 0.049 0.88 (0.75–1.02) 0.098
Rec 0.54 (0.31–0.92) 0.022 0.78 (0.49–1.23) 40.1 0.98 (0.48–0.95) 0.022
rs939453 ARMC8 Geno 0.68 (0.51–0.90) 1.10 (0.88–1.38) 1.10 (0.71–1.01)
0.62 (0.43–0.89) 0.017 1.07 (0.81–1.41) 40.1 0.79 (0.64–0.98) 0.068
Allelic 0.78 (0.65–0.93) 0.0056 0.96 (0.84–1.1) 40.1 0.89 (0.80–0.99) 0.025
Dom 1.47 (1.11–1.93) 0.0062 0.91 (0.74–1.13) 40.1 0.83 (0.71–0.98) 0.27
Rec 0.77 (0.56–1.04) 0.091 0.99 (0.78–1.25) 40.1 0.88 (0.73–1.05) 0.163
rs1131597 SLCO2A1 Geno 0.77 (0.59–1.01) 0.97 (0.79–1.19) 0.97 (0.76–1.04)
0.47 (0.31–0.72) 0.0015 1.07 (0.79–1.47) 40.1 0.80 (0.63–1.02) 40.1
Allelic 0.71 (0.59–0.86) 0.00038 1.02 (0.88–1.17) 40.1 0.89 (0.80–0.99) 0.043
Dom 0.70 (0.54–0.90) 0.005 0.99 (0.82–1.20) 40.1 0.88 (0.75–1.01) 0.068
Rec 0.54 (0.36–0.81) 0.0026 1.09 (0.81–1.46) 40.1 0.85 (0.67–1.07) 0.164
rs10934954 PIK3R4 Geno 1.13 (0.86–1.47) 0.93 (0.75–1.15) 1.01 (0.85–1.18)
1.95 (1.09–3.51) 0.068 1.25 (0.79–1.98) 40.1 1.50 (1.05–2.13) 0.081
Allelic 1.25 (1.01–1.54) 0.042 1.01 (0.87–1.15) 40.1 1.10 (0.97–1.25) 40.1
Dom 1.21 (0.94–1.56) 0.146 0.97 (0.79–1.18) 40.1 1.06 (0.91–0.24) 0.450
Rec 1.87 (1.05–3.34) 0.031 1.28 (0.82–2.02) 40.1 1.49 (1.05–2.12) 0.025
rs2071387 RBP1 Geno 1.17 (0.89–1.55) 1.02 (0.82–1.26) 1.04 (0.88–1.23)
0.38 (0.17–0.87) 0.023 1.40 (0.81–2.43) 40.1 0.57 (0.36–0.90) 0.034
Allelic 0.95 (0.75–1.20) 0.672 0.93 (0.78–1.11) 40.1 0.93 (0.81–1.07) 40.1
Dom 1.06 (0.81–1.39) 0.662 0.95 (0.77–1.17) 40.1 0.98 (0.84–1.15) 40.1
Rec 0.37 (0.16–0.83) 0.012 0.72 (0.42–1.24) 40.1 0.56 (0.36–0.88) 0.010
Abbreviations: CI¼ confidence interval; Dom¼ dominant; Geno¼ genotypic; OR¼ odds ratio; Rec¼ recessive; SNP¼ single-nucleotide polymorphism. ORs and unadjusted
P-values are shown for discovery, replication and overall phases for each of them. Significant P-values are depicted in bold.
Table 3 Association results for six selected SNPs were evaluated in two cohorts (CORGI and VQ58) in an external GWAS, either by checking the
original variant or a proxy SNP highly correlated with it (r240.7).
Present in I5? Present in I3? Proxy r2 and D0 P (CORGI) P (VQ58)
rs1444601 Yes Yes — 0.2653 0.7039
rs13088006 No No rs6769437 0.818 1.000 0.5816 0.4101
rs939453 No No rs7631734 0.869 0.964 0.7984 0.2922
rs1131597 No No rs7616492 0.762 1.000 0.1273 0.9246
rs10934954 No No rs2200368 1.000 1.000 0.6710 0.0899
rs2071387 Yes Yes — 0.7243 0.8671
Abbreviations: GWAS¼ genome-wide association study; SNP¼ single-nucleotide polymorphism; I5¼ Illumina HumanHap550; I3¼ Illumina HumanHap300 (Illumina, San Diego,
CA, USA).
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strongly involved in CRC carcinogenesis, and its signalling is
dependent on both receptors, TGFBR1 and TGFBR2. Although
mutations in the TGFBR2 gene have been explicitly associated
with CRC, the contribution of TGFBR1 to the CRC is less clear. (Valle
et al, 2008) suggested that germline TGFBR1 allele-specific expression
could confer an increased CRC risk, although very recently, another
study refuted this hypothesis (Seguı´ et al, 2011).
Another interesting gene located on region 9q22 is GALNT12, a
member of the N-acetylgalactosaminyltransferase gene superfamily
involved in protein glycosylation and highly expressed in the
colon. Aberrant glycosylation is a known alteration that leads to
the onset and progression of many cancers, including CRC.
Recently, a study found germline mutations in the GALNT12 gene
in some CRC patients (Guda et al, 2009). We also included in our
study eight GALNT12 variants to further investigate whether the
SNP variability of this gene could be involved in genetic
susceptibility to CRC. However, we did not find any statistical
significant association.
Although using a through and extensive two-phase case– control
association study, we were not able to find any new susceptibility
loci for CRC risk within these regions. However, some of the
SNPs in region 3q22 showed interesting results in the joint analysis
combining both cohorts (1361 CRC cases and 1342 controls),
especially rs1444601 in TOPBP1 and rs13088006 in CDV3,
which maintained statistical significance with an unadjusted
P-value in all phases. TOPBP1 (topoisomerase DNA II-binding
protein 1) represents a very interesting candidate for CRC genetic
susceptibility as it contains multiple BRCT domains, the
C-terminal portion of the BRCA-1 gene, and it has a critical role
in the control of DNA damage and replication checkpoint
(Gong et al, 2010). On the other hand, CDV3 (carnitine
deficiency-associated gene expressed in ventricle 3), also known
as H41, seems to be involved in cell proliferation and altered
in gastric cancer (Oh et al, 2005). It is noteworthy that the
TOPBP1 and CDV3 genes lie next to each other in 3q22 and
rs1444601 and rs13088006 are only 34 kb apart. Therefore, it was
interesting to know whether they co-segregated. Unfortunately,
there were no available data for rs13088006 in HapMap. However,
we used our own genotyping data in Haploview and found that
they are not in the same haplotype block and segregate
independently (r2¼ 0.35).
When we checked our association results in two cohorts
described in a previous GWAS (Tomlinson et al, 2007), none of
these six variants were significantly associated with CRC risk.
There could be differences in terms of the allele frequencies and
linkage disequilibrium patterns between CORGI/VQ58 and
EPICOLON data. This may explain the lack of replication of our
suggestive hits in this external GWAS. In addition, the magnitude
of the effect of a risk allele may differ between populations because
of gene– gene or gene–environment interactions.
Finally, as limitations to our study, it should be commented that
our cohort sample size is probably not large enough to be able to
reach stronger conclusions for the analysed variants. However, our
study (1416 CRC cases and 1424 controls for EPICOLON cohorts)
had an estimated 80% power to detect an OR as low as 1.26 with an
MAF of 0.30, 1.25 for a MAF down to 0.20 or 1.31 for a MAF down
to 0.08, assuming a dominant model and a¼ 0.05. It must be noted
also that our conclusions were obtained in the EPICOLON cohorts
and results were additionally corroborated in the CORGI and
VQ58 cohorts, adding together 3721 CRC cases and 4970 controls.
In addition, it should be commented that our results apply only for
the analysed SNPs as we did not whatsoever comprehensively
cover all possible low-penetrance genetic variants within the
selected genes. Nevertheless, gene/SNP selection was biased to
include genes with a plausible function in cancer and SNPs with a
putative functional effect.
In conclusion, none of the 172 SNPs initially analysed in our
study could be formally associated with CRC risk. However,
variants in TOPBP1 and CDV3 showed interesting results and may
have an effect on CRC risk. Despite our negative results, we
consider additional case– control studies in larger CRC cohorts
and meta-analysis could be useful to confirm or refute the role of
TOPBP1 and CDV3 variants in CRC susceptibility.
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